Omada Health Inc(US:OMDA)2025-11-06 21:30Financial Performance & Growth - Total member growth reached 53%, increasing from 543,000 in Q3 2024 to 831,000 in Q3 2025[14] - Revenue grew by 49%, from $455 million in Q3 2024 to $680 million in Q3 2025[14] - Non-GAAP Gross Profit increased by 56%, from $297 million in Q3 2024 to $464 million in Q3 2025, with Gross Margins at 652% and 682% respectively[14] - Net loss improved by $6 million, decreasing from $(92) million in Q3 2024 to $(32) million in Q3 2025[14] - Adjusted EBITDA grew by $75 million, increasing from $(51) million in Q3 2024 to $24 million in Q3 2025[14] Business Model & Customer Base - The company has over 2,000 customers[16, 134] and a customer retention rate of over 90%[16, 134] - Over 20 million individuals have benefits coverage for one or more programs[16, 80] - The company's revenue model is recurring, tied to member success, and billable through payer claims for certain customers[16, 18] Market Opportunity & GLP-1 Strategy - The total current addressable market is estimated at $414 billion for prediabetes, $173 billion for diabetes, $316 billion for hypertension, and $448 billion for musculoskeletal conditions[24] - Enhanced GLP-1 Care Track members experienced 28% greater weight loss compared to members not enrolled in the track over the first 16 weeks[101] - Enhanced GLP-1 Care Track members maintained weight loss at 16 weeks post-discontinuation, with an average weight change of 08%[100, 101]